Targeting a membrane protein called TMEM16F may help reduce the spread of toxic clumps, or aggregates, of alpha-synuclein — a…
Articles by Patricia Inácio, PhD
The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s…
Zimmer Biomet announced that it has acquired select exclusive rights to distribute NeuroOne’s OneRF Ablation System, a…
A researcher at the University of Rhode Island has received nearly $500,000 in federal funding to investigate the neuronal changes…
Adding Cerevance’s investigational oral therapy solengepras (CVN424) to standard Parkinson’s disease treatment significantly decreased off time, when…
Amprion said it has raised the initial $6 million of a $15 million financing deal that will help develop…
The first patient with early Parkinson’s disease has been dosed in Ventyx Biosciences‘ Phase 2a clinical trial of…
Regeneron has joined the data syndication program for Koneksa‘s LEARNS study that’s assessing the potential of digital biomarkers…
Understanding and identifying epigenetic changes — those that affect gene activity without altering a gene’s DNA sequence — in blood…
A Phase 1 trial of ALX-001, an investigational therapy for neurodegenerative conditions, has dosed the first patient with Parkinson’s…